Omega 3 Prescription Drugs Market To Reach $1.80 Billion By 2030

Omega 3 Prescription Drugs Market Growth & Trends

The global omega 3 prescription drugs market size is expected to reach USD 1.80 billion in 2030 and is expected to expand at a CAGR of 4.90% by 2030. The growth of the industry is attributed to the rising cases of Cardiovascular Diseases (CVDs) and altered dietary practices. An elevated level of triglycerides in the blood is now known to be associated with an increased risk of cardiovascular disease. According to the European Society of Cardiology in 2021, 17.9 million people die from CVDs each year, making it the leading cause of death worldwide. Furthermore, due to the expanding product application potential in medicines, omega 3-based pharmaceutical product launches by industry participants are anticipated to boost its growth.

For instance, in 2020, the U.S. FDA authorized a new cardiovascular indication and label expansion for the omega-3 medication VASCEPA, manufactured by U.S.-based Amarin Corporation. An increase in triglycerides can cause artery narrowing, which raises the risk of heart attack and stroke. Pancreatitis, an inflammation of the pancreas, can result from extremely high levels as well. Triglyceride levels rise as a result of diabetes and obesity, which is a widespread issue. An average of 25% of American adults have high borderline blood alcohol concentrations. The omega-3 fatty acid medications are prescribed only for triglycerides levels above 500 mg/dl as approved by the U.S. FDA. The omega 3 prescription drugs demonstrated a significant market movement during the COVID-19 pandemic.

This is owing to their significant role in the management of CVD patients. For instance, in August 2021, Woodward Pharma Services LLC announced the acquisition of LOVAZA from GlaxoSmithKline. The company further aims to educate consumers and providers to facilitate higher adoption of the product. Moreover, multiple R&D studies are being conducted for lowering triglycerides; combined and analyzed findings from 17 organized and randomized clinical trials on elevated triglyceride levels, suggest that prescription omega-3 fatty acid medication can reduce levels by 20-30%. This is expected to create high product demand. 

 Request a free sample copy or view report summary: Omega 3 Prescription Drugs Market Report

Omega 3 Prescription Drugs Market Report Highlights

• Lovaza is projected to experience moderate growth opportunities during the forecast period.

• Cardiovascular dominated the market and accounted for the largest revenue share of 86.8% in 2024

• Retail pharmacy dominated the market and accounted for the largest revenue share of 53.6% in 2024 due to its wide accessibility and consumer convenience

• The online pharmacy segment is expected to witness moderate growth due to the increasing consumer preference for convenient and accessible healthcare solutions

• North America dominated the global omega 3 prescription drugs market with a share of 42.9% in 2024 and is anticipated to grow significantly over the forecast period.

Omega 3 Prescription Drugs Market Segmentation

Grand View Research has segmented the global omega 3 prescription market report based on drugs, application, distribution channel, and regions

Omega 3 Prescription Drugs Drug Outlook (Revenue, USD Million, 2018 - 2030)

• Vascepa

• Lovaza

• Others

Omega 3 Prescription Drugs Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cardiovascular

• Others

Omega 3 Prescription Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

Omega 3 Prescription Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Omega 3 Prescription Drugs Market

• Amarin Pharmaceuticals Ireland Limited

• Woodward Pharma Services LLC

• Mankind Pharma

• GLW Pharma GMBH

• CSPC Pharmaceutical Group Limited

• Sofgen

• WILSHIRE PHARMACEUTICALS, INC.

• Sun Pharmaceutical Industries Ltd.

• PuraCap Pharmaceutical LLC

• ChartwellPharma

• Amneal Pharmaceuticals LLC